drugset / Trial / NCT00605033

A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)

NCT00605033

Phase 4 Completed 241 enrolled Indivior Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Post-marketing commitment to the European Medicines Agency to conduct a prospective, controlled study of the transfer from Subutex to Suboxone.

Timeline

Start
2008-03
Primary completion
2009-04
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 4 mg Subcutaneous
Comparator Buprenorphine Other / unclassified 24 mg Subcutaneous
Comparator Naloxone Small molecule 1 mg Subcutaneous
Comparator Naloxone Small molecule 6 mg Subcutaneous

Indications